Guideline Recommendations for Azelastine in Allergic Rhinitis and Allergic Conjunctivitis

Nasal Therapy for Moderate‑to‑Severe Allergic Rhinitis

Azelastine 0.1%–0.15% nasal spray provides rapid symptom relief (within 30 minutes) and achieves overall efficacy comparable to intranasal corticosteroids for most nasal symptoms, making it a first‑line option for patients with moderate‑to‑severe disease, especially when combined with a corticosteroid for those inadequately controlled on monotherapy. 1
In patients whose symptoms remain uncontrolled after ≥ 2 weeks of optimal intranasal corticosteroid therapy, adding azelastine (137 µg per spray, 1 spray/nostril twice daily) is preferred over increasing the steroid dose or adding an oral antihistamine. 1
Azelastine monotherapy can be used for breakthrough nasal symptoms, delivering noticeable relief within 30 minutes. 1

The azelastine‑fluticasone combination yields > 40 % greater overall symptom reduction than either component alone in moderate‑to‑severe allergic rhinitis, representing the most effective intranasal regimen currently available. 1
Clinical benefit with the combination is evident from the first day of treatment and reaches maximal response several days earlier than with fluticasone or azelastine monotherapy. 1
The combination also provides meaningful additional relief of ocular itching, tearing, and throat irritation that intranasal corticosteroids alone cannot achieve. 1

The most frequent adverse event is a bitter taste (dysgeusia), reported in 2 %–14 % of users; it is generally well tolerated. 1
Mild somnolence occurs in 0.4 %–1.7 % of patients, a rate comparable to placebo. 1
Epistaxis rates with azelastine (both monotherapy and combination) are similar to placebo and lower than those observed with high‑dose intranasal corticosteroids. 1

Azelastine 0.05 % ophthalmic solution is FDA‑approved for the treatment of eye itching associated with allergic conjunctivitis, delivering rapid onset of effect (≈ 3 minutes) and lasting approximately 8 hours. (Citation not provided; omitted from list)

Adding an oral antihistamine to an intranasal corticosteroid regimen does not improve nasal symptom control and should be avoided. 1
Patients should be counseled about the possibility of a bitter taste with nasal spray (2 %–14 % incidence) to promote adherence. 1
For enhanced comfort, refrigerate azelastine eye drops before instillation; the cooling effect can improve patient satisfaction. 2